Preliminary evaluation of the radiotherapeutic efficacy of 131I-atorvastatin in rats with hepatocellular carcinoma

2020 ◽  
Vol 31 (11) ◽  
Author(s):  
Nourihan S. Farrag ◽  
Abeer M. Amin
Keyword(s):  
Hepatocellular Carcinoma ◽  
Preliminary Evaluation

Preliminary Evaluation of [11C]MAGL-0519 as a Promising PET Ligand for the Diagnosis of Hepatocellular Carcinoma

2022 ◽  
pp. 105620
Author(s):  
Tuo Shao ◽  
Zhen Chen ◽  
Ran Cheng ◽  
Lee Collier ◽  
Lee Josephson ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Preliminary Evaluation

8. Preliminary evaluation of 131I Lipiodol and FDG PET in hepatocellular carcinoma

2000 ◽  
Vol 21 (5) ◽  
pp. 475
Author(s):  
G. OʼConnell ◽  
J. Roberts ◽  
M. Fulham ◽  
R. Mansberg ◽  
J. Towson
Keyword(s):  
Hepatocellular Carcinoma ◽  
Fdg Pet ◽  
Preliminary Evaluation

scholarly journals Syntheses and preliminary evaluation of [18F]AlF-NOTA-G-TMTP1 for PET imaging of high aggressive hepatocellular carcinoma

2016 ◽  
Vol 11 (4) ◽  
pp. 262-271 ◽  
Author(s):  
Yesen Li ◽  
Deliang Zhang ◽  
Ying Shi ◽  
Zhide Guo ◽  
Xinying Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pet Imaging ◽  
Preliminary Evaluation

scholarly journals Preliminary evaluation of indigenous90Y-labelled microspheres for therapy of hepatocellular carcinoma

2016 ◽  
Vol 143 (7) ◽  
pp. 74 ◽  
Author(s):  
Meera Venkatesh ◽  
Suresh Subramanian ◽  
Usha Pandey ◽  
Pradip Chaudhari ◽  
Monica Tyagi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Preliminary Evaluation

A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4598-4598 ◽  
Author(s):  
V. Gruenwald ◽  
L. Wilkens ◽  
M. Gebel ◽  
T. F. Greten ◽  
S. Kubicka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Response ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Chromosome 1 ◽  
Preliminary Evaluation ◽  
Open Label ◽  
Prior Therapy ◽  
Egfr Expression ◽  
Tumor Biopsies

4598 Background: Hepatocellular carcinoma (HCC) express the epidermal growth factor receptor (EGFR), and EGFR-targeting therapies are known to block tumor growth. We tested the activity of cetuximab (CET) in HCC and evaluated serial tumor biopsies for biomarker analyses. Methods: Patients (pts) with advanced or metastatic HCC with ECOG = 2 and adequate organ function were eligible. Prior therapy was permitted. CET was given iv weekly (400 mg/m2 loading dose, 250 mg/m2 thereafter). The primary endpoint was the rate of progression-free survival (PFS) at 24 wks. Serial tumor biopsies were performed prior to treatment, after 4 wks and at time of progression. 32 pts were enrolled. 27 pts are evaluable for tumor response. Results: Stable disease (SD) was achieved in 44.4% (12 pts) for at least 8 weeks of treatment. 55.6% failed to respond to CET (15 pts). The median time to progression (TTP) for all pts was 8.0 wks. Pts, which were stable for more than 8 wks achieved a median TTP of 22.5 wks (11–48 wks) compared to a median TTP of 6.0 wks (3–8 wks) in progressive pts. No treatment-related severe adverse events were noted throughout the study. Preliminary evaluation of surrogate markers showed no correlation with cytogenetic abnormalities based on FISH analyses for chromosome 1 and 8. Furthermore, only 5 of 21 tumor specimens were positive for EGFR expression without gene amplification, evaluated by FISH analyses. Serial tumor specimens are available in 5 responding and in 7 non-responding pts for changes of p27 and p21 expression. p27 and p21 were upregulated simultaneously in 60% (3/5 pts) of responding pts, whereas in pts with treatment failure p27 and p21 expression was detectable in 14% (1/7 pts) only. Conclusions: Cytogenetic aberrations of chromosome 1 and 8 failed to predict response to CET. In a subgroup of pts with SD >8 weeks, induction of p21 and p27 were associated with prolonged TTP >20 wks. Further evaluation of p21 and p27 as early molecular tumor response is warranted to identify pts, which benefit from anti-EGFR therapies. [Table: see text] No significant financial relationships to disclose.

Preliminary Evaluation of a Weibull Function for Fitting Slow-Component Eye Velocity over the Time Course of Caloric-Induced Nystagmus

1989 ◽  
Vol 32 (3) ◽  
pp. 681-687 ◽  
Author(s):  
C. Formby ◽  
B. Albritton ◽  
I. M. Rivera
Keyword(s):  
Time Course ◽  
Slow Component ◽  
Weibull Function ◽  
Preliminary Evaluation ◽  
Mathematical Function ◽  
Before And After ◽  
Best Fitting ◽  
Eye Velocity ◽  
Fitting Parameters ◽  
Weibull Equation

We describe preliminary attempts to fit a mathematical function to the slow-component eye velocity (SCV) over the time course of caloric-induced nystagmus. Initially, we consider a Weibull equation with three parameters. These parameters are estimated by a least-squares procedure to fit digitized SCV data. We present examples of SCV data and fitted curves to show how adjustments in the parameters of the model affect the fitted curve. The best fitting parameters are presented for curves fit to 120 warm caloric responses. The fitting parameters and the efficacy of the fitted curves are compared before and after the SCV data were smoothed to reduce response variability. We also consider a more flexible four-parameter Weibull equation that, for 98% of the smoothed caloric responses, yields fits that describe the data more precisely than a line through the mean. Finally, we consider advantages and problems in fitting the Weibull function to caloric data.

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment

Hepatocellular carcinoma

1982 ◽  
Vol 118 (1) ◽  
pp. 69-70 ◽  
Author(s):  
A. J. Bennett
Keyword(s):  
Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document